<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896440</url>
  </required_header>
  <id_info>
    <org_study_id>Pediatric ondansetron QTc</org_study_id>
    <nct_id>NCT01896440</nct_id>
  </id_info>
  <brief_title>Heart Safety Study of Ondansetron in Children Receiving Chemotherapy</brief_title>
  <official_title>The Effects of Ondansetron on Myocardial Repolarization in Children Receiving Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will study the effects of ondansetron on measurements of electrical activity in the heart&#xD;
      to make sure doses we are using to prevent nausea and vomiting in children receiving&#xD;
      chemotherapy are safe.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children receiving chemotherapy for cancer at the Jimmy Everest Center for Cancer and Blood&#xD;
      Disorders in Children also often receive an IV dose of an antiemetic for prophylaxis. The&#xD;
      most common antiemetics used are in the family of 5HT3 antagonists, specifically granisetron&#xD;
      and ondansetron. Prior to a recent recommendation by the FDA, we have used ondansetron 0.45&#xD;
      mg/kg IV. Based on adult ECG data, the recommended dose of ondansetron has been changed to no&#xD;
      greater than 0.15 mg/kg. We have prior studies showing that the bigger dose is better at&#xD;
      preventing nausea and vomiting. Therefore we are studying ECG data in patients receiving&#xD;
      ondansetron and chemotherapy. Each subject will have two identical cycles of chemotherapy.&#xD;
      Prior to the first of the two cycles they will be randomized to receive one of two doses of&#xD;
      ondansetron with the first cycle and the other dose with the second cycle. The two doses are&#xD;
      the recommended dose of 0.15 mg/kg and a higher dose of 0.3 mg/kg. The dose level the patient&#xD;
      receives each cycle will be blinded to the investigator and the subject.&#xD;
&#xD;
      Prior to the first dose of investigational ondansetron, the patient will have an ECG. This&#xD;
      ECG will be repeated 30 minutes after the ondansetron is administered and just before&#xD;
      chemotherapy administration, and repeated again 30 minutes later. The change in the QTc&#xD;
      intervals will be calculated by two independent pediatric cardiologists who are also blinded&#xD;
      to the ondansetron dose level received. This process will be repeated with the next course of&#xD;
      chemotherapy, with the second dose of ondansetron. Our goal is to see if there is an&#xD;
      appreciable difference between the two doses in the QTc interval changes they induce.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    FDA did not approve&#xD;
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in QTc interval</measure>
    <time_frame>Day 1 to 2 months</time_frame>
    <description>QTc intervals will be estimated by performing ECGs on patients pre-investigational drug administration and post-investigational drug administration. The change in the QTc interval between the two ECGs for each investigational dose is the primary endpoint.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Malignant Childhood Neoplasm</condition>
  <arm_group>
    <arm_group_label>Group A - standard ondansetron dose first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A will receive the standard dose of ondansetron (0.15 mg/kg) with the first cycle of chemotherapy and the high dose (0.3 mg/kg) with second cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - high dose ondansetron first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B patients will receive the higher dose of ondansetron (0.3 mg/kg) with the first cycle of chemotherapy and the standard dose (0.15 mg/kg) with the second.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)</description>
    <arm_group_label>Group A - standard ondansetron dose first</arm_group_label>
    <arm_group_label>Group B - high dose ondansetron first</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 6 months to 18 years&#xD;
&#xD;
          -  Diagnosis of cancer and receiving 2 identical cycles of chemotherapy within 2 months&#xD;
             of each other&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cardiac conduction anomalies, myocardial infarction, structural heart&#xD;
             abnormalities (even if repaired)&#xD;
&#xD;
          -  Pregnant or of child-bearing age and unwilling to take a pregnancy test&#xD;
&#xD;
          -  Potassium or calcium outside of reference range at screening&#xD;
&#xD;
          -  Liver enzymes (AST/ALT) or bilirubin &gt;/= 2 x the upper limit of normal at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rene Y McNall-Knapp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Campbell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>July 1, 2013</study_first_submitted>
  <study_first_submitted_qc>July 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <last_update_submitted>October 4, 2013</last_update_submitted>
  <last_update_submitted_qc>October 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oklahoma</investigator_affiliation>
    <investigator_full_name>Rene Y McNall-Knapp, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Ondansetron</keyword>
  <keyword>Cardiac repolarization</keyword>
  <keyword>QTc interval</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

